Literature DB >> 34306928

Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma.

Kevin C Miller1, John P Marinelli1, Jeffrey R Janus2, Ashish V Chintakuntlawar3, Robert L Foote4, Michael J Link2,5, Garret Choby2, Jamie J Van Gompel2,5.   

Abstract

Esthesioneuroblastoma (ENB) is a rare olfactory malignancy that can present with locally advanced disease. At our institution, patients with ENB in whom the treating surgeon believes that a margin-negative resection is initially not achievable are selected to undergo induction with chemotherapy with or without radiotherapy prior to surgery. In a retrospective review of 61 patient records, we identified six patients (10%) treated with this approach. Five of six patients (83%) went on to definitive surgery. Prior to surgery, three of five patients (60%) had a partial response after induction therapy, whereas two of five (40%) had stable disease. Microscopically margin-negative resection was achieved in four of five (80%) of the patients who went on to surgery, while one patient had negative margins on frozen section but microscopically positive margins on permanent section. Three of five patients (60%) recurred after surgery; two of these patients died with recurrent/metastatic ENB. In summary, induction therapy may facilitate margin-negative resection in locally advanced ENB. Given the apparent sensitivity of ENB to chemotherapy and radiotherapy, future prospective studies should investigate the optimal multidisciplinary approach to improve long-term survival in this rare disease. Thieme. All rights reserved.

Entities:  

Keywords:  esthesioneuroblastoma; induction; neoadjuvant; outcomes; therapy

Year:  2020        PMID: 34306928      PMCID: PMC8289526          DOI: 10.1055/s-0039-3402026

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  24 in total

1.  Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma.

Authors:  Kevin C Miller; John P Marinelli; Jamie J Van Gompel; Michael J Link; Jeffrey R Janus; Robert L Foote; Katharine A Price; Joaquin Garcia; Michael Rivera; Ashish V Chintakuntlawar
Journal:  Head Neck       Date:  2018-12-10       Impact factor: 3.147

Review 2.  Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

Authors:  E A McElroy; J C Buckner; J E Lewis
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

Review 3.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

4.  Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.

Authors:  Eduardo M Diaz; Richard H Johnigan; Colin Pero; Adel K El-Naggar; Dianna B Roberts; James L Barker; Franco DeMonte
Journal:  Head Neck       Date:  2005-02       Impact factor: 3.147

5.  Esthesioneuroblastoma in children and adolescent: experience on 11 cases with literature review.

Authors:  Maria El Kababri; Jean L Habrand; Dominique Valteau-Couanet; Nathalie Gaspar; Christelle Dufour; Odile Oberlin
Journal:  J Pediatr Hematol Oncol       Date:  2014-03       Impact factor: 1.289

6.  Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.

Authors:  Moran Amit; Ahmed S Abdelmeguid; Teemaranawich Watcherporn; Hideaki Takahashi; Samantha Tam; Diana Bell; Renata Ferrarotto; Bonnie Glisson; Michael E Kupferman; Dianna B Roberts; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Esthesioneuroblastoma: the UCLA experience 1970-1990.

Authors:  P Dulguerov; T Calcaterra
Journal:  Laryngoscope       Date:  1992-08       Impact factor: 3.325

9.  Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival.

Authors:  Jamie J Van Gompel; Caterina Giannini; Kerry D Olsen; Eric Moore; Manolo Piccirilli; Robert L Foote; Jan C Buckner; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2012-10

10.  Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.

Authors:  Naomi Kiyota; Makoto Tahara; Satoshi Fujii; Mitsuhiko Kawashima; Takashi Ogino; Hironobu Minami; Ryuichi Hayashi; Atsushi Ohtsu
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

View more
  1 in total

1.  Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection.

Authors:  Emily E Karp; Jamie J Van Gompel; Garret Choby
Journal:  J Neurol Surg Rep       Date:  2022-07-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.